Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of triamcinolone acetonide (a synthetic corticosteroid) and curcumin (a natural polyphenol derived from turmeric). This combination is primarily used for treating oral lichen planus (OLP), particularly erosive and ulcerative forms. The combination has demonstrated superior efficacy compared to triamcinolone acetonide alone in reducing symptoms, decreasing lesion size, and improving inflammatory markers. Triamcinolone acetonide provides anti-inflammatory effects through corticosteroid action, while curcumin contributes antioxidant, anti-inflammatory, and antifungal properties that may help prevent complications associated with corticosteroid use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone acetonide + curcumin.